WILMINGTON, Mass.--(BUSINESS WIRE)--Sirtex, a leading developer of targeted and innovative liver cancer therapies, provided an update on clinical initiatives regarding SIR-Spheres® microspheres. Highlights include the results of two independent studies in Belgium and Italy published recently in the Journal of Clinical Oncology and the British Journal of Cancer, respectively. The studies reconfirmed evidence from earlier research that established “significant clinical benefits from the use of targeted radioactive SIR-Spheres microspheres as an effective option for patients with inoperable liver cancer.”
